Latest Health News
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX),…
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
February 23, 2026 17:10 ET | Source: Kyntra Bio FG-3246 and enzalutamide…
argenx to Present at TD Cowen 46th Annual Healthcare Conference
February 23, 2026 01:00 ET | Source: argenx SE February 23, 2026Amsterdam,…
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
February 22, 2026 16:00 ET | Source: Dyne Therapeutics, Inc. - Late-breaking…
Gyder Surgical announces first commercial surgical cases in the United States performed by Dr. Paul M. Lombardi, M.D., at the Tri-County Orthopedics Joint Replacement Institute outpatient center
PALO ALTO, Calif. and MULGRAVE, Australia, Feb. 22, 2026 (GLOBE NEWSWIRE) --…
Thermobalancing therapy emerges as drug-free option for BPH, chronic prostatitis, back pain and kidney stones
Oxford, UK, Feb. 21, 2026 (GLOBE NEWSWIRE) -- Therapeutic Dr Allen’s Devices…
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
February 20, 2026 15:10 ET | Source: Eupraxia Pharmaceuticals Inc. VICTORIA, British…
U.S. Food and Drug Administration (FDA) Accepts Tevas New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the…
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares
DUBLIN, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB),…
